Heterocyclic compounds that inhibit Rev-RRE function and human immunodeficiency virus type 1 replication

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 9, 2008, Pages 3169-3179

  Shuck Lee, Deidra ^a   Fei, Fei Chen ^a   Willard, Ryan ^a   Raman, Sharmila ^a   Ptak, Roger ^b   Hammarskjold, Marie Louise ^a   Rekosh, David ^a,c  

^a UNIVERSITY OF VIRGINIA   (United States)

^b SOUTHERN RESEARCH INSTITUTE   (United States)

^c UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HETEROCYCLIC COMPOUND; REV PROTEIN;

ARTICLE; ASSAY; CELL LINE; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; LIFE CYCLE; NONHUMAN; PRIORITY JOURNAL; VIRUS ISOLATION; VIRUS LIKE AGENT; VIRUS REPLICATION;

ANIMALS; ANTI-HIV AGENTS; CELL LINE; CERCOPITHECUS AETHIOPS; COS CELLS; GENE PRODUCTS, REV; GENES, ENV; HETEROCYCLIC COMPOUNDS; HIV INFECTIONS; HIV-1; HUMANS; LEUKOCYTES, MONONUCLEAR; MICROBIAL SENSITIVITY TESTS; VIRUS REPLICATION;

EID: 50949114650     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.00274-08     Document Type: Article

References (70)

1. Askjaer, P., T. H. Jensen, J. Nilsson, L. Englmeier, and J. Kjems. 1998. The specificity of the CRM1-Rev nuclear export signal interaction is mediated by RanGTP. J. Biol. Chem. 273:33414-33422.
2. Berger, J., C. Aepinus, M. Dobrovnik, B. Fleckenstein, J. Hauber, and E. Bohnlein. 1991. Mutational analysis of functional domains in the HIV-1 Rev trans-regulatory protein. Virology 183:630-635.
3. Bevec, D., and J. Hauber. 1997. Eukaryotic initiation factor 5A activity and HIV-1 Rev function. Biol. Signals 6:124-133.
4. Bogerd, H. P., A. Echarri, T. M. Ross, and B. R. Cullen. 1998. Inhibition of human immunodeficiency virus Rev and human T-cell leukemia virus Rex function, but not Mason-Pfizer monkey virus constitutive transport element activity, by a mutant human nucleoporin targeted to Crm1. J. Virol. 72:8627-8635.
5. Boschelli, D. H. 2002. 4-Anilino-3-quinolinecarbonitriles: an emerging class of kinase inhibitors. Curr. Top. Med. Chem. 2:1051-1063.
6. Bray, M., S. Prasad, J. W. Dubay, E. Hunter, K. T. Jeang, D. Rekosh, and M. L. Hammarskjold. 1994. A small element from the Mason-Pfizer monkey virus genome makes human immunodeficiency virus type 1 expression and replication Rev-independent. Proc. Natl. Acad. Sci. USA 91:1256-1260.
7. Briz, V., E. Poveda, and V. Soriano. 2006. HIV entry inhibitors: mechanisms of action and resistance pathways. J. Antimicrob. Chemother. 57:619-627.
8. Buckheit, R. W., Jr., and R. Swanstrom. 1991. Characterization of an HIV-1 isolate displaying an apparent absence of virion-associated reverse transcriptase activity. AIDS Res. Hum. Retrovir. 7:295-302.
9. Cannon, P., S. H. Kim, C. Ulich, and S. Kim. 1994. Analysis of Tat function in human immunodeficiency virus type 1-infected low-level-expression cell lines U1 and ACH-2. J. Virol. 68:1993-1997.
10. Ciccarelli, R. B., L. A. Winter, R. Lorenz, A. L. Harris, A. C. Crawford, T. R. Bailey, B. Singh, M.-L. Hammarskjold, D. Rekosh, and J. V. Hughes. 1994. Inhibition of the cellular Rev response and HIV-1 replication by 8-alkyl-2-(4-pyridyl)pyrido[2,3-d] pyrimidin-5(8H)-ones. Antivir. Chem. Chemother. 5:169-175.
11. Clouse, K. A., D. Powell, I. Washington, G. Poli, K. Strebel, W. Farrar, P. Barstad, J. Kovacs, A. S. Fauci, and T. M. Folks. 1989. Monokine regulation of human immunodeficiency virus-1 expression in a chronically infected human T cell clone. J. Immunol. 142:431-438.
12. Cochrane, A. W., C. H. Chen, and C. A. Rosen. 1990. Specific interaction of the human immunodeficiency virus Rev protein with a structured region in the env mRNA. Proc. Natl. Acad. Sci. USA 87:1198-1202.
13. Correll, T., and O. M. Klibanov. 2008. Integrase inhibitors: a new treatment option for patients with human immunodeficiency virus infection. Pharmacotherapy 28:90-101.
14. Daefler, S., M. E. Klotman, and S. F. Wong. 1990. Trans-activating rev protein of the human immunodeficiency virus 1 interacts directly and specifically with its target RNA. Proc. Natl. Acad. Sci. USA 87:4571-4575.
15. D'Agostino, D. M., B. K. Felber, J. E. Harrison, and G. N. Pavlakis. 1992. The Rev protein of human immunodeficiency virus type 1 promotes polysomal association and translation of gag/pol and vpu/env mRNAs. Mol. Cell. Biol. 12:1375-1386.
16. Daly, T. J., K. S. Cook, G. S. Gray, T. E. Maione, and J. R. Rusche. 1989. Specific binding of HIV-1 recombinant Rev protein to the Rev-responsive element in vitro. Nature 342:816-819.
17. Dayton, A. I., J. G. Sodroski, C. A. Rosen, W. C. Goh, and W. A. Haseltine. 1986. The trans-activator gene of the human T cell lymphotropic virus type III is required for replication. Cell 44:941-947.
18. DeJong, E. S., C. E. Chang, M. K. Gilson, and J. P. Marino. 2003. Proflavine acts as a Rev inhibitor by targeting the high-affinity Rev binding site of the Rev. responsive element of HIV-1. Biochemistry 42:8035-8046.
19. Dimitrov, D. S., R. L. Willey, H. Sato, L. J. Chang, R. Blumenthal, and M. A. Martin. 1993. Quantitation of human immunodeficiency virus type 1 infection kinetics. J. Virol. 67:2182-2190.
20. Fang, J., S. Kubota, and R. J. Pomerantz. 2002. A trans-dominant negative HIV type 1 Rev with intact domains of NLS/NOS and NES. AIDS Res. Hum. Retrovir. 18:705-709.
21. Fasken, M. B., R. Saunders, M. Rosenberg, and D. W. Brighty. 2000. A leptomycin B-sensitive homologue of human CRM1 promotes nuclear export of nuclear export sequence-containing proteins in Drosophila cells. J. Biol. Chem. 275:1878-1886.
22. Felber, B. K., M. Hadzopoulou-Cladaras, C. Cladaras, T. Copeland, and G. N. Pavlakis. 1989. Rev protein of human immunodeficiency virus type 1 affects the stability and transport of the viral mRNA. Proc. Natl. Acad. Sci. USA 86:1496-1499.
23. Folks, T. M., K. A. Clouse, J. Justement, A. Rabson, E. Duh, J. H. Kehrl, and A. S. Fauci. 1989. Tumor necrosis factor alpha induces expression of human immunodeficiency virus in a chronically infected T-cell clone. Proc. Natl. Acad. Sci. USA 86:2365-2368.
24. Folks, T. M., J. Justement, A. Kinter, C. A. Dinarello, and A. S. Fauci. 1987. Cytokine-induced expression of HIV-1 in a chronically infected promonocyte cell line. Science 238:800-802.
25. Fornerod, M., M. Ohno, M. Yoshida, and I. W. Mattaj. 1997. CRM1 is an export receptor for leucine-rich nuclear export signals. Cell 90:1051-1060.
26. Fouts, D. E., H. L. True, K. A. Cengel, and D. W. Celander. 1997. Site-specific phosphorylation of the human immunodeficiency virus type-1 Rev protein accelerates formation of an efficient RNA-binding conformation. Biochemistry 36:13256-13262.
27. Gruter, P., C. Tabernero, C. von Kobbe, C. Schmitt, C. Saavedra, A. Bachi, M. Wilm, B. K. Felber, and E. Izaurralde. 1998. TAP, the human homolog of Mex67p, mediates CTE-dependent RNA export from the nucleus. Mol. Cell 1:649-659.
28. Hadzopoulou-Cladaras, M., B. K. Felber, C. Cladaras, A. Athanassopoulos, A. Tse, and G. N. Pavlakis. 1989. The rev (trs/art) protein of human immunodeficiency virus type 1 affects viral mRNA and protein expression via a cis-acting sequence in the env region. J. Virol. 63:1265-1274.
29. Hamasaki, K., and A. Ueno. 2001. Aminoglycoside antibiotics, neamine and its derivatives as potent inhibitors for the RNA-protein interactions derived from HIV-1 activators. Bioorg. Med. Chem. Lett. 11:591-594.
30. Hammarskjöld, M.-L., J. Heimer, B. Hammarskjöld, I. Sangwan, L. Albert, and D. Rekosh. 1989. Regulation of human immunodeficiency virus env expression by the rev gene product. J. Virol. 63:1959-1966.
31. Hammarskjöld, M. L. 1997. Regulation of retroviral RNA export. Semin. Cell Dev. Biol. 8:83-90.
32. Heaphy, S., C. Dingwall, I. Ernberg, M. J. Gait, S. M. Green, J. Karn, A. D. Lowe, M. Singh, and M. A. Skinner. 1990. HIV-1 regulator of virion expression (Rev) protein binds to an RNA stem-loop structure located within the Rev response element region. Cell 60:685-693.
33. Heguy, A. 1997. Inhibition of the HIV Rev transactivator: a new target for therapeutic intervention. Front. Biosci. 2:d283-d297.
34. Henderson, B. R., and P. Percipalle. 1997. Interactions between HIV Rev and nuclear import and export factors: the Rev nuclear localisation signal mediates specific binding to human importin-beta. J. Mol. Biol. 274:693-707.
35. Hofmann, W., B. Reichart, A. Ewald, E. Muller, I. Schmitt, R. H. Stauber, F. Lottspeich, B. M. Jockusch, U. Scheer, J. Hauber, and M. C. Dabauvalle. 2001. Cofactor requirements for nuclear export of Rev response element (RRE)- and constitutive transport element (CTE)-containing retroviral RNAs. An unexpected role for actin. J. Cell Biol. 152:895-910.
36. Holland, S. M., N. Ahmad, R. K. Maitra, P. Wingfield, and S. Venkatesan. 1990. Human immunodeficiency virus Rev protein recognizes a target sequence in Rev-responsive element RNA within the context of RNA secondary structure. J. Virol. 64:5966-5975.
37. Hope, T. J., X. J. Huang, D. McDonald, and T. G. Parslow. 1990. Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif. Proc. Natl. Acad. Sci. USA 87:7787-7791.
38. Jin, L., B. W. Guzik, Y. C. Bor, D. Rekosh, and M. L. Hammarskjöld. 2003. Tap and NXT promote translation of unspliced mRNA. Genes Dev. 17: 3075-3086.
39. Lacourciere, K. A., J. T. Stivers, and J. P. Marino. 2000. Mechanism of neomycin and Rev peptide binding to the Rev responsive element of HIV-1 as determined by fluorescence and NMR spectroscopy. Biochemistry 39: 5630-5641.
40. Lee, T. C., B. A. Sullenger, H. F. Gallardo, G. E. Ungers, and E. Gilboa. 1992. Overexpression of RRE derived sequences inhibits HIV-1 replication in CEM cells. New Biol. 4:66-74.
41. Malim, M. H., W. W. Freimuth, J. Liu, T. J. Boyle, H. K. Lyerly, B. R. Cullen, and G. J. Nabel. 1992. Stable expression of transdominant Rev protein in human T cells inhibits human immunodeficiency virus replication. J. Exp. Med. 176:1197-1201.
42. Malim, M. H., J. Hauber, S. V. Le, J. V. Maizel, and B. R. Cullen. 1989. The HIV-1 rev trans-activator acts through a structured target sequence to activate nuclear export of unspliced viral mRNA. Nature 338:254-257.
43. Malim, M. H., L. S. Tiley, D. F. McCarn, J. R. Rusche, J. Hauber, and B. R. Cullen. 1990. HIV-1 structural gene expression requires binding of the Rev trans-activator to its RNA target sequence. Cell 60:675-683.
44. Morwick, T., A. Berry, J. Brickwood, M. Cardozo, K. Catron, M. DeTuri, J. Emeigh, C. Homon, M. Hrapchak, S. Jacober, S. Jakes, P. Kaplita, T. A. Kelly, J. Ksiazek, M. Liuzzi, R. Magolda, C. Mao, D. Marshall, D. McNeil, A. Prokopowicz III, C. Sarko, E. Scouten, C. Sledziona, S. Sun, J. Watrous, J. P. Wu, and C. L. Cywin. 2006. Evolution of the thienopyridine class of inhibitors of IkappaB kinase-beta: part I: hit-to-lead strategies. J. Med. Chem. 49:2898-2908.
45. Nabel, G. J., B. A. Fox, L. Post, C. B. Thompson, and C. Woffendin. 1994. A molecular genetic intervention for AIDS - effects of a transdominant negative form of Rev. Hum. Gene Ther. 5:79-92.
46. Nakaya, T., S. Iwai, K. Fujinaga, E. Otsuka, and K. Ikuta. 1997. Inhibition of HIV-1 replication by targeting the Rev protein. Leukemia 11(Suppl. 3):134-137.
47. Otero, G. C., M. E. Harris, J. E. Donello, and T. J. Hope. 1998. Leptomycin B inhibits equine infectious anemia virus Rev and feline immunodeficiency virus Rev function but not the function of the hepatitis B virus posttranscriptional regulatory element. J. Virol. 72:7593-7597.
48. Perales, C., L. Carrasco, and M. E. Gonzalez. 2005. Regulation of HIV-1 env mRNA translation by Rev protein. Biochim. Biophys. Acta 1743:169-175.
49. Pollard, V. W., and M. H. Malim. 1998. The HIV-1 Rev protein. Annu. Rev. Microbiol. 52:491-532.
50. Ratmeyer, L., M. L. Zapp, M. R. Green, R. Vinayak, A. Kumar, D. W. Boykin, and W. D. Wilson. 1996. Inhibition of HIV-1 Rev-RRE interaction by diphenylfuran derivatives. Biochemistry 35:13689-13696.
51. Reeves, J. D., and A. J. Piefer. 2005. Emerging drug targets for antiretroviral therapy. Drugs 65:1747-1766.
52. Rey, F., F. Barre-Sinoussi, H. Schmidtmayerova, and J. C. Chermann. 1987. Detection and titration of neutralizing antibodies to HIV using an inhibition of the cytopathic effect of the virus on MT4 cells. J. Virol. Methods 16:239-249.
53. Rosen, C. A., E. Terwilliger, A. Dayton, J. G. Sodroski, and W. A. Haseltine. 1988. Intragenic cis-acting art gene-responsive sequences of the human immunodeficiency virus. Proc. Natl. Acad. Sci. USA 85:2071-2075.
54. Sanchez-Velar, N., E. B. Udofia, Z. Yu, and M. L. Zapp. 2004. hRIP, a cellular cofactor for Rev function, promotes release of HIV RNAs from the perinuclear region. Genes Dev. 18:23-34.
55. Srinivasakumar, N., N. Chazal, C. Helga-Maria, S. Prasad, M. L. Hammarskjöld, and D. Rekosh. 1997. The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines. J. Virol. 71:5841-5848.
56. Symensma, T. L., S. Baskerville, A. Yan, and A. D. Ellington. 1999. Polyvalent Rev decoys act as artificial Rev-responsive elements. J. Virol. 73:4341-4349.
57. Takahashi, T., K. Hamasaki, A. Ueno, and H. Mihara. 2001. Construction of peptides with nucleobase amino acids: design and synthesis of the nucleobase-conjugated peptides derived from HIV-1 Rev and their binding properties to HIV-1 RRE RNA. Bioorg. Med. Chem. 9:991-1000.
58. Truant, R., and B. R. Cullen. 1999. The arginine-rich domains present in human immunodeficiency virus type 1 Tat and Rev function as direct importin beta-dependent nuclear localization signals. Mol. Cell. Biol. 19:1210-1217.
59. Turpin, J. A. 2003. The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets. Expert Rev. Anti-Infect. Ther. 1:97-128.
60. Turpin, J. A., R. W. Buckheit, Jr., D. Derse, M. Hollingshead, K. Williamson, C. Palamone, M. C. Osterling, S. A. Hill, L. Graham, C. A. Schaeffer, M. Bu, M. Huang, W. M. Cholody, C. J. Michejda, and W. G. Rice. 1998. Inhibition of acute-, latent-, and chronic-phase human immunodeficiency virus type 1 (HIV-1) replication by a bistriazoloacridone analog that selectively inhibits HIV-1 transcription. Antimicrob. Agents Chemother. 42:487-494.
61. Wehrly, K., and B. Chesebro. 1997. p24 antigen capture assay for quantification of human immunodeficiency virus using readily available inexpensive reagents. Methods 12:288-293.
62. Woffendin, C., U. Ranga, Z. Yang, L. Xu, and G. J. Nabel. 1996. Expression of a protective gene prolongs survival of T cells in human immunodeficiency virus-infected patients. Proc. Natl. Acad. Sci. USA 93:2889-2894.
63. Wolff, B., J. J. Sanglier, and Y. Wang. 1997. Leptomycin B is an inhibitor of nuclear export: inhibition of nucleo-cytoplasmic translocation of the human immunodeficiency virus type 1 (HIV-1) Rev protein and Rev-dependent mRNA. Chem. Biol. 4:139-147.
64. Xiao, G., A. Kumar, K. Li, C. T. Rigl, M. Bajic, T. M. Davis, D. W. Boykin, and W. D. Wilson. 2001. Inhibition of the HIV-1 rev-RRE complex formation by unfused aromatic cations. Bioorg. Med. Chem. 9:1097-1113.
65. Yedavalli, V. S., C. Neuveut, Y. H. Chi, L. Kleiman, and K. T. Jeang. 2004. Requirement of DDX3 DEAD box RNA helicase for HIV-1 Rev-RRE export function. Cell 119:381-392.
66. Yu, Z., N. Sanchez-Velar, I. E. Catrina, E. L. Kittler, E. B. Udofia, and M. L. Zapp. 2005. The cellular HIV-1 Rev cofactor hRIP is required for viral replication. Proc. Natl. Acad. Sci. USA 102:4027-4032.
67. Zapp, M. L., and M. R. Green. 1989. Sequence-specific RNA binding by the HIV-1 Rev protein. Nature 342:714-716.
68. Zapp, M. L., S. Stern, and M. R. Green. 1993. Small molecules that selectively block RNA binding of HIV-1 Rev protein inhibit Rev function and viral production. Cell 74:969-978.
69. Zapp, M. L., D. W. Young, A. Kumar, R. Singh, D. W. Boykin, W. D. Wilson, and M. R. Green. 1997. Modulation of the Rev-RRE interaction by aromatic heterocyclic compounds. Bioorg. Med. Chem. 5:1149-1155.
70. Zolotukhin, A. S., and B. K. Felber. 1999. Nucleoporins Nup98 and Nup214 participate in nuclear export of human immunodeficiency virus type 1 Rev. J. Virol. 73:120-127.